Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie
Conditions: Oncology; Infusion Reaction Interventions: Drug: Nivolumab; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Durvalumab; Drug: Atezolizumab; Drug: Bevacizumab; Drug: Trastuzumab Sponsor: Isala Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 11, 2023 Category: Research Source Type: clinical trials
Phase IB Followed by Phase II Study of Trastuzumab Combined With Autologous T Cells Expressing an Antibody-dependent Cell Cytotoxicity Receptor (ADCC-R) and an Erythropoietin Receptor (Epo-R) in HER2+ Advanced Breast Cancer and Other Solid Tumors
Conditions: HER2+ Advanced Breast Cancer; Other Solid Tumors Interventions: Drug: ADCC-R-Epo-R T-cells + Trastuzumab; Drug: Erythropoietin beta; Drug: Fludarabine and Cyclophosphosphamide Sponsor: National University Hospital, Singapore Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2023 Category: Research Source Type: clinical trials
